Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the infectious diseases society of America

Clinical Infectious Diseases

Volumn 58, Issue 1, 2014, Pages

  Aberg, Judith A ^a   Gallant, Joel E ^b,c   Ghanem, Khalil G ^c   Emmanuel, Patricia ^d   Zingman, Barry S ^e   Horberg, Michael A ^f  

^a BELLEVUE HOSPITAL CENTER   (United States)

^b Southwest CARE Center   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f Mid Atlantic Permanente Research Institute   (United States)

Author keywords

guidelines; HIV; HIV metabolic; HIV monitoring; HIV vaccines; primary care; sexually transmitted diseases

Indexed keywords

ABACAVIR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHICKENPOX VACCINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; INFLUENZA VACCINE; METHADONE; NON PRESCRIPTION DRUG; POLIOMYELITIS VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; ANTIRETROVIRUS AGENT; CREATININE; HLA B57 ANTIGEN; TESTOSTERONE; VIRUS RNA;

ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; CHLAMYDIASIS; COMORBIDITY; CONTRACEPTION; CREATININE CLEARANCE; DISEASE TRANSMISSION; EMPORIATRICS; EVIDENCE BASED PRACTICE; FAMILY HISTORY; FOLLOW UP; GONORRHEA; HEALTH CARE PERSONNEL; HLA SYSTEM; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LUMBAR PUNCTURE; MAMMOGRAPHY; MATERNAL CARE; MEDICAL SOCIETY; MENOPAUSE; MIXED INFECTION; NONHUMAN; OCCUPATIONAL EXPOSURE; PAPILLOMAVIRUS INFECTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUBLICATION; RISK REDUCTION; SEXUALLY TRANSMITTED DISEASE; THORAX RADIOGRAPHY; TOXOPLASMA GONDII; TRANSGENDERISM; TRICHOMONIASIS; URINALYSIS; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS HEPATITIS; ANTIVIRAL RESISTANCE; HEPATITIS B; PROGNOSIS; SURVIVAL; SYPHILIS; TESTOSTERONE BLOOD LEVEL; TUBERCULOSIS; VERTICAL TRANSMISSION; WART VIRUS; HIV METABOLIC; HIV MONITORING; HIV VACCINES; HUMAN IMMUNODEFICIENCY VIRUS; METHODOLOGY; PRIMARY HEALTH CARE;

GUIDELINES; HIV; HIV METABOLIC; HIV MONITORING; HIV VACCINES; PRIMARY CARE; SEXUALLY TRANSMITTED DISEASES;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; PRIMARY HEALTH CARE;

EID: 84891352634     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit665     Document Type: Article

References (123)

1. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:651-81.
2. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Diseases Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-27.
3. Guyatt GH, Oxman AD, Kunz R, et al. Going from evidence to recommendations. BMJ 2008; 336:1049-51.
4. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-6.
5. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337:a744.
6. Guyatt GH, Oxman AD, Kunz R, et al. Incorporating considerations of resources use into grading recommendations. BMJ 2008; 336:1170-3.
7. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336:1106-10.
8. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ 2008; 336:995-8.
9. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010; 59:1-25.
10. AIDSinfo. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents, 2013. Available at: http://aidsinfo.nih.gov/guidelines/. Accessed 15 September 2013.
11. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts =300 cells/?L and HIV-1 viral suppression? Clin Infect Dis 2013.
12. Field MJ, Lohr KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academies Press, 1990:8.
13. New York State Department of Health AIDS Institute. Care of the HIV-infected transgender patient, 2013. Available at: http://www. hivguidelines.org/clinical-guidelines/transgender/care-of-the-hiv- infectedtransgender-patient/. Accessed 15 September 2013.
14. New York State Department of Health AIDS Institute. Mental health care for people with HIV infection: clinical guidelines for the primary care practitioner. Available at: http://www.hivguidelines.org/Content. aspx?PageID=261. Accessed 6 February 2009.
15. Gannon P, Khan MZ, Kolson DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 2011; 24:275-83.
16. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013; 56:1004-17.
17. Nasrullah M, Wesolowski LG, Meyer WA 3rd, et al. Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. AIDS 2013; 27:731-7.
18. Centers for Disease Control and Prevention. Detection of acute HIV infection in two evaluations of a new HIV diagnostic testing algorithm-United States, 2011-2013. MMWR Morb Mortal Wkly Rep 2013; 62:489-94.
19. Panel on Antiretroviral Therapy and Medical Management of HIVInfected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection, 2012. Available at: http://aidsinfo.nih.gov/contentfiles/ lvguidelines/pediatricguidelines.pdf. Accessed 15 September 2013.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2013. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/Adultand AdolescentGL.pdf. Accessed 15 September 2013.
21. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
22. Soriano V, Geretti AM, Perno CF, et al. Optimal use of maraviroc in clinical practice. AIDS 2008; 22:2231-40.
23. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50:499-505.
24. Tungsiripat M, Drechsler H, Sarlone C, Amyot K, Laffey E, Aberg J. Prevalence and significance of G6PD deficiency in patients of an urban HIV clinic. J Int Assoc Physicians AIDS Care 2008; 7:88-90.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-97.
26. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559-85.
27. American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52 (RR-11):1-77.
28. Doshi S, Chen TF, Zapata J, et al. Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. Int J Infect Dis 2012; 16:e518-21.
29. Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. MMWR Recomm Rep 1997; 46(RR-15):1-10.
30. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIVinfected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56:230-8.
31. AIDSinfo. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children, 2013. Available at: http://aidsinfo.nih.gov/guidelines/. Accessed 15 September 2013.
32. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-85.
33. Advisory Committee for Immunization Practices (ACIP). Recommended adult immunization schedule: United States, 2013. Ann Intern Med 2013; 158:XXX-XXX.
34. Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191:1435-41.
35. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 years and Adults Aged 19 Years and Older-United States, 2013 Source: MMWR Supplements, February 1, 2013; 62:1-21.
36. Centers for Disease Control and Prevention (CDC), Health Resources and Services Administration, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. Incorporating HIV prevention into the medical care of persons living with HIV. Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2003; 52(RR-12):1-24.
37. Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period-are they opportunities for treatment? J Viral Hepat 2011; 18:229-36.
38. Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis 2006; 194:247-55.
39. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4): 1-40.
40. Centers for Disease Control and Prevention. FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012; 61:212.
41. Benson C, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo-controlled trial. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle,Washington, 2012. Abstract 96.
42. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
43. Paramsothy P, Duerr A, Heilig CM, et al. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J Acquir Immune Defic Syndr 2004; 35:484-91.
44. Wright TC Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:2120-9.
45. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114-9.
46. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005; 293:1471-6.
47. Moyer VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 156:880-91, W312.
48. US Department of Veteran Affairs. Anal dysplasia, 2011. Available at: http://www.hiv.va.gov/provider/manual-primary-care/anal-dysplasia.asp. Accessed 15 September 2013.
49. New York State Department of Health AIDS Institute. Anal dysplasia and cancer, 2007. Available at: http://www.hivguidelines.org/clinicalguidelines/ adults/anal-dysplasia-and-cancer/. Accessed 15 September 2013.
50. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55:197-204.
51. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-53.
52. Kotton CN, Freedman DO. CDC health information for international travel (Yellow Book). Chapter 8: advising travelers with specific needs, immunocompromised travelers, 2014. Available at: http://wwwnc.cdc. gov/travel/yellowbook/2014/chapter-8-advising-travelers-withspecific-needs/ immunocompromised-travelers. Accessed 15 September 2013.
53. Minkoff HL, Eisenberger-Matityahu D, Feldman J, Burk R, Clarke L. Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol 1999; 180:824-36.
54. Pantanowitz L, Connolly JL. Pathology of the breast associated with HIV/AIDS. Breast J 2002; 8:234-43.
55. Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest 2002; 20:452-7.
56. No authors listed. ACOG practice bulletin. Breast cancer screening. Number 42, April 2003. Int J Gynaecol Obstet 2003; 81:313-23.
57. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 146:511-5.
58. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-Infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, 2013. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed 15 September 2013.
59. American Academy of Pediatrics Committee on Pediatric AIDS. HIV testing and prophylaxis to prevent mother-to-child transmission in the United States. Pediatrics 2008; 122:1127-34.
60. US Public Health Service. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, 2012. Available at: http://aidsinfo.nih.gov/guidelines/html/3/perinatalguidelines/0/. Accessed 15 September 2013.
61. Persaud D, Gay H, Ziemniak C, et al. Functional HIV cure after very early ART of an infected infant. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013. Abstract 48LB.
62. Havens PL, Mofenson LM. Evaluation and management of the infant exposed to HIV-1 in the United States. Pediatrics 2009; 123: 175-87.
63. Dunn D, Woodburn P, Duong T, et al. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008; 197:398-404.
64. American Academy of Pediatrics. Human immunodeficiency virus infection. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red book: 2009 report of the committee on infectious diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2009.
65. Kourtis AP, Bansil P, Posner SF, Johnson C, Jamieson DJ. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics 2007; 120:e236-43.
66. Verweel G, Saavedra-Lozano J, van Rossum AM, Ramilo O, de Groot R. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence. Pediatr Infect Dis J 2006; 25:987-94.
67. Wiener L, Mellins CA, Marhefka S, Battles HB. Disclosure of an HIV diagnosis to children: history, current research, and future directions. J Dev Behav Pediatr 2007; 28:155-66.
68. American Academy of Pediatrics (AAP). Disclosure of illness status to children and adolescents with HIV infection. American Academy of Pediatrics Committee on Pediatrics AIDS. Pediatrics 1999; 103:164-6.
69. Van Dyke RB, Patel K, Siberry GK, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr 2011; 57:165-73.
70. Nozyce ML, Lee SS,Wiznia A, et al. A behavioral and cognitive profile of clinically stable HIV-infected children. Pediatrics 2006; 117:763-70.
71. Koenig LJ, Pals SL, Chandwani S, et al. Sexual transmission risk behavior of adolescents with HIV acquired perinatally or through risky behaviors. J Acquir Immune Defic Syndr 2010; 55:380-90.
72. Brogly SB, Watts DH, Ylitalo N, et al. Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health 2007; 97:1047-52.
73. Robinson P, Cavalier Y, Davison C, Donovan M, Fox D. Adolescent transition workbook, 2006. Available at: http://www.aids-ed.org/aidsetc?page= etres-display&resource=etres-269
74. New York State Department of Health AIDS Institute. Transitioning HIV-infected adolescents into adult care, 2011. Available at: http://www.hivguidelines.org/clinical-guidelines/adolescents/ transitioninghiv-infected-adolescents-into-adult-care/. Accessed 15 September 2013.
75. Maturo D, Powell A, Major-Wilson H, Sanchez K, De Santis JP, Friedman LB. Development of a protocol for transitioning adolescents with HIV infection to adult care. J Pediatr Health Care 2011; 25:16-23.
76. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-96.
77. Ho JE, Deeks SG, Hecht FM, et al. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 2010; 24:1897-905.
78. No authors listed. Executive summary: standards of medical care in diabetes-2013. Diabetes Care 2013; 36:(suppl 1):4-10.
79. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-46.
80. No authors listed. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013; 36(suppl 1):S67-74.
81. Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA. Glycated hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS 2012; 26:197-201.
82. Inzucchi SE. Diagnosis of diabetes. N Engl J Med 2012; 367:542-50.
83. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21:2473-82.
84. Lin D, Rieder MJ. Interventions for the treatment of decreased bone mineral density associated with HIV infection. Cochrane Database Syst Rev 2007: CD005645.
85. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl JMed 2011; 365:493-505.
86. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-43.
87. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
88. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229-34.
89. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
90. Bakken S, Holzemer WL, Brown MA, et al. Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS. AIDS Patient Care STDS 2000; 14:189-97.
91. Giordano TP, Gifford AL, White AC Jr, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007; 44:1493-9.
92. Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48:248-56.
93. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med 2004; 19:1096-103.
94. Malcolm SE, Ng JJ, Rosen RK, Stone VE. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care 2003; 15:251-61.
95. Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIVinfected persons to care. AIDS 2005; 19:423-31.
96. Stone VE. Optimizing the care of minority patients with HIV/AIDS. Clin Infect Dis 2004; 38:400-4.
97. Willard S, Angelino AF. The need for sociocultural awareness to maximize treatment acceptance and adherence in individuals initiating HIV therapy. J Int Assoc Physicians AIDS Care 2008; 7:S17-21.
98. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003; 17:169-77.
99. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30(suppl 2):S171-6.
100. Gallant JE, Adimora AA, Carmichael JK, et al. Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition. Clin Infect Dis 2011; 53:1043-50.
101. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA 2001; 286: 2857-64.
102. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47:384-90.
103. Flanigan TP, Mitty JA. The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult. Clin Infect Dis 2006; 42:1636-8.
104. Horberg MA, Aberg JA, Cheever LW, Renner P, O'Brien Kaleba E, Asch SM. Development of national and multiagency HIV care quality measures. Clin Infect Dis 2010; 51:732-8.
105. New York State Department of Health AIDS Institute. Clinical guidelines, 2013. Available at: http://www.hivguidelines.org/clinicalguidelines/. Accessed 15 September 2013.
106. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55:245-64.
107. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55(RR-14):1-17.
108. Committee on Pediatric AIDS. Adolescents and HIV infection: the pediatrician's role in promoting routine testing. Pediatrics 2011; 128:1023-29.
109. Centers for Disease Control and Prevention. Immunization schedules, 2012. Available at: http://www.cdc.gov/vaccines/schedules/index.html. Accessed 15 September 2013.
110. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol 2013; 34:875-92.
111. New York State Department of Health AIDS Institute. Post-exposure prophylaxis, 2012. Available at: http://www.hivguidelines.org/ clinicalguidelines/post-exposure-prophylaxis/. Accessed 15 September 2013.
112. No authors listed. Human immunodeficiency virus infection. In: Larry KP, ed. Red book: American Academy of Pediatrics, 2012:418-39.
113. New York State Department of Health AIDS Institute. Perioperative management of HIV-infected patients, 2012. Available at: http://www. hivguidelines.org/clinical-guidelines/adults/perioperativemanagement-of-hiv- infected-patients/. Accessed 15 September 2013.
114. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13:77-108.
115. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
116. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr 2005; 39:307-12.
117. Grennan T, Walmsley S. Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class. J Int Assoc Physicians AIDS Care 2009; 8:354-63.
118. Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep 2009; 11: 84-92.
119. Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr 2012; 60:158-64.
120. Yu CY, Campbell SE, Sponseller CA, et al. Steady-state pharmacokinetic interactions of darunavir/ritonavir with pitavastatin in healthy adult volunteers. In: XIX International AIDS Conference, Washington, DC, 2012. Abstract TUPE053.
121. Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol 2012; 52:1725-38.
122. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47:570-8.
123. Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010; 24:77-83.